Evolus Projects FDA Nod For Evolysse Gels Within 90 Days, Eyes Q2 2025 U.S. Rollout; Reports $79M Q4 2024 Revenue, FY24 Revenue $266.3M; Expects $345M-$355M Net Revenue And $230M-$240M Non-GAAP Expenses For 2025; Plans 8-10% Revenue From Evolysse, Estyme Gels
Benzinga
21 Jan
Expects U.S. Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability1
Preliminary Unaudited Net Revenue of $79.0 Million for the Fourth Quarter 2024, Representing 30% Growth Over the Prior Year
Preliminary Unaudited Net Revenue of $266.3 Million for the Full-Year 2024, Representing 32% Growth Over the Prior Year and at the Top of the Company's Guidance
Expects U.S. Food and Drug Administration (FDA) Approval Within 90 Days for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid (HA) Gels; U.S. Launch Planned for Q2 2025, A Full Quarter Ahead of Prior Timeline
2025 Net Revenue Guidance of $345 Million to $355 Million, Which Represents 30% to 33% Growth from Preliminary 2024 Results; Evolysse™ and Estyme® Injectable HA Gels Anticipated to Contribute 8-10% of Total Revenue for the Full-Year 2025
2025 Non-GAAP Operating Expenses Expected to be $230 Million to $240 Million, with Expected Profitability1 for the Full-Year 2025
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.